Injection of recombinant FGF21 inhibited RAS and attenuated inflammation-driven tumor formation, proposing intervention at the RAS-PPARγ-FGF21 axis as a novel target to treat or prevent pancreatic cancer. This evidence concerns the gene FGF21 and familial pancreatic carcinoma.